Effect of Aerobic Exercise on Peak Oxygen Consumption, VE/VCO2 Slope, and Health-Related Quality of Life in Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction: a Systematic Review and Meta-Analysis

2019 ◽  
Vol 21 (11) ◽  
Author(s):  
Mansueto Gomes-Neto ◽  
André Rodrigues Durães ◽  
Lino Sergio Rocha Conceição ◽  
Leonardo Roever ◽  
Tong Liu ◽  
...  
Circulation ◽  
2000 ◽  
Vol 102 (11) ◽  
pp. 1245-1251 ◽  
Author(s):  
Karin S. Coyne ◽  
Conor F. Lundergan ◽  
Deneane Boyle ◽  
Samuel W. Greenhouse ◽  
Yasmine C. Draoui ◽  
...  

2020 ◽  
Author(s):  
Mulubirhan Tirfe ◽  
Alemseged Beyene ◽  
Haileselassie Berhane ◽  
Ephrem Engidawork ◽  
Tewolde Teklu

Abstract Background: Heart failure (HF) is associated with severe complications, hospitalization, and poor quality of life. Patients with heart failure had poor physical and emotional symptoms, functional status and worse health outcomes.Objective: The aim of this systematic review and meta-analysis will be to investigate whether pharmacist intervention is effective in improving health related quality of life (HRQoL) and clinical outcomes among patients with heart failure.Method: Systematic review and meta-analysis will be conducted. Published journals in English and indexed in Medline (PubMed), Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, and Google scholar will be searched from 1990 to December 2019. Data will be extracted by one author and will be approved by other two authors independently. Data will be analyzed in accordance with the Cochrane handbook. Standardized mean differences will be used as an estimate of the effect size. Quality of included studies will be assessed using the modified Downs and Black checklist. Analysis for the dichotomous outcome studies will be converted into standardized mean difference and present with 95% confidence intervals. The review is approved in the International Prospective Register of Systematic Reviews (PROSPERO) with registration ID CRD42020158236.Discussion: Currently there are important gaps on the effectiveness of pharmacist intervention in improving health-related quality of life and clinical outcomes. We believe this review will provide comprehensive evidence on the effectiveness of pharmacist intervention among patients with HF.


2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
C Proudfoot ◽  
A.F Fonseca ◽  
R Lahoz ◽  
S Corda ◽  
S Cotton ◽  
...  

Abstract Background and purpose Heart Failure (HF) is associated with symptoms such as dyspnoea and fatigue which can impact patients' health related quality of life (HRQoL). This study aimed to characterize and assess the HRQoL of patients with HF and left-ventricular ejection fraction (LVEF) <40% versus those with ≥40%-60%. Methods A cross-sectional study of patients with HF was conducted in France, Germany, Italy, Spain and United Kingdom. Patient record forms (PRFs) were completed by 257 cardiologists and 158 general practitioners (GPs) for consecutively consulting patients. The same patients were invited to provide patient-reported outcomes including self-completion questionnaires, Minnesota Living with Heart Failure Questionnaire (MLHFQ) and EQ-5D-5L VAS. Results 204 HF patients with LVEF <40% (mean age 67.7 years) and 600 patients with LVEF ≥40–60% (mean age 68.9 years) were included. Proportion of males was significantly higher in the lower LVEF group (73.5% vs. 61.2%, p=0.0017). Overall, the patients with lower LVEF more frequently presented with comorbidities than those with LVEF ≥40–60% (p<0.05, Figure 1). NYHA stage III/IV (35.8%/7.4% vs. 15.3%/0.8%) as well as self-reported HF symptoms were more frequently reported in the lower LVEF group (p<0.05, Figure 1). Similarly, patients with LVEF <40% reported statistically significantly worse HRQoL compared to those with LVEF ≥40–60% (Table 1). Conclusions The HRQoL of all HF patients with LVEF ≤60% appears impacted, while those with LVEF <40% had significantly worse HRQoL than those with LVEF ≥40–60%. These differences in HRQoL may not only be related to the LVEF but also to the overall characteristics of these patients. Addressing the HRQoL burden for patients should be a key aspect of HF management strategies for all HF patients. Funding Acknowledgement Type of funding source: Private company. Main funding source(s): Novartis Pharma AG


Author(s):  
Carlos Zaror ◽  
Andrea Matamala‐Santander ◽  
Montse Ferrer ◽  
Fernando Rivera‐Mendoza ◽  
Gerardo Espinoza‐Espinoza ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document